Pigmentary glaucoma: does a 120° ab-interno trabeculotomy help
Official title: Clinical Characteristics of Pigmentary Glaucoma and Efficacy Analysis of Ab-interno 120° Trabeculotomy: A Case Series Study
Run by Zhongnan Hospital · NCT07713056 · Data updated 2026-11-12
This study will see if performing an ab-interno 120° trabeculotomy can lower eye pressure and reduce medication needs in people with pigmentary glaucoma over six months.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 16 Years to 80 Years |
| Sex | All |
| Enrollment | 11 (estimated) |
| Sponsor | Zhongnan Hospital Academic / other |
| Locations | 1 site (Wuhan, Hubei) |
| Status | Recruiting |
| Started | April 1, 2026 |
| Main results expected | September 30, 2026 |
| Study ends | September 30, 2026 |
| Registry record updated | July 20, 2026 |
| Trial ID | NCT07713056 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults diagnosed with pigmentary glaucoma who are undergoing primary, isolated ab-interno 120° trabeculotomy and have complete preoperative and at least six months of postoperative data.
✕Probably not a fit
Patients with exfoliation syndromes, other glaucoma types, ocular trauma, prior ocular surgeries, or those unable to complete six months of follow-up may not benefit or may be excluded from conclusions.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a single-center, retrospective case series of pigmentary glaucoma patients treated with primary, isolated ab-interno 120° trabeculotomy at Zhongnan Hospital. Researchers will collect baseline demographics, eye exams, and prior treatments to describe typical features of pigmentary glaucoma. The primary endpoint is intraocular pressure at six months postoperatively, with secondary observations on medication use, visual field and RNFL stability, and any surgical complications. The goal is to provide clinical evidence to guide individualized surgical decisions for pigmentary glaucoma. The study does not involve a randomized control or prospective design.
Why it matters
Potential benefit: If successful, patients may experience lower eye pressure and reduced need for glaucoma medications after the procedure.
How similar studies have gone: Previous studies of similar angle-surgery approaches have shown varying success; this study adds data specific to pigmentary glaucoma in a retrospective, single-center setting.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Meet the clinical diagnostic criteria for pigmentary glaucoma, with typical signs of pigment dispersion syndrome, extensive trabecular meshwork pigmentation, pathological intraocular pressure elevation, glaucomatous optic nerve damage, and characteristic visual field defects; * Underwent primary isolated ab-interno 120° trabeculotomy as the initial surgical treatment; * Have complete preoperative and postoperative examination data, including slit-lamp biomicroscopy, gonioscopy, intraocular pressure, visual field, and OCT RNFL measurements; * Able to complete regular follow-up for at least 6 months postoperatively. Exclusion Criteria: * Patients with exfoliation syndrome, exfoliative glaucoma, or other types of primary or secondary glaucoma; * Patients with a history of ocular trauma, intraocular surgery, uveitis, severe retinopathy, or other ocular diseases affecting intraocular pressure and visual function assessment; * Patients who underwent combined procedures such as concurrent cataract surgery or other anti-glaucoma surgeries during the operation; * Patients with severe systemic diseases, cognitive or psychiatric disorders that prevent cooperation with examinations and follow-up; * Patients with missing key clinical or follow-up data that preclude efficacy and prognosis evaluation.
Where it's running
-
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China Recruiting
Study contacts
- Principal investigator: Wen Zeng, doctor — Zhongnan Hospital
- Study coordinator: Min Ke, doctor
- Email: Keminyk@163.com
- Phone: 18672395959
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Patient quality of life after different glaucoma surgeries
This project uses the NEI-VFQ-25 vision questionnaire to see if adults who have PreserFlo MicroShunt, trabeculectomy, or non-penetrating deep sclerectomy report different quality of life after surgery.
-
iStent infinite plus iDose TR for moderate-to-severe open-angle glaucoma
This trial will see if placing an iStent infinite device together with an iDose TR travoprost implant can lower eye pressure and reduce glaucoma eye drops for people with moderate to severe open-angle glaucoma not controlled by medication or laser.
-
CAIX-targeted PET/CT imaging in solid tumors
Researchers are testing a CAIX-targeted PET/CT imaging agent to see if it detects and reflects CAIX levels in solid tumors like clear cell renal cell carcinoma, NSCLC, and breast cancer.
-
Temporal interference stimulation in Parkinson's disease: STN vs GPi targets
This study tests whether stimulating the subthalamic nucleus or the globus pallidus internus with temporal interference stimulation improves motor symptoms in people with Parkinson's disease.
-
Bowel Sounds and Day-to-Day Recovery After Colorectal Cancer Surgery
This study will test whether monitoring bowel sounds before and after colorectal cancer surgery can predict how quickly patients recover bowel function and resume eating.
-
Multi-omics analysis linking zonular laxity and primary angle‑closure glaucoma
It will test whether molecular differences in eye fluid, blood, and the anterior lens capsule link zonular laxity to primary angle‑closure glaucoma in adults aged 50 and older.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.